Journal of Medicinal Chemistry
Article
adjuvantic properties of innate immune stimuli. Hum. Vaccines 2009, 5,
381−394.
(24) Ichinohe, T.; Watanabe, I.; Ito, S.; Fujii, H.; Moriyama, M.;
Tamura, S.; Takahashi, H.; Sawa, H.; Chiba, J.; Kurata, T.; Sata, T.;
Hasegawa, H. Synthetic double-stranded RNA poly(I:C) combined
with mucosal vaccine protects against influenza virus infection. J. Virol.
2005, 79, 2910−2919.
(25) Ma, Y.; Ross, A. C. The anti-tetanus immune response of
neonatal mice is augmented by retinoic acid combined with
polyriboinosinic:polyribocytidylic acid. Proc. Natl. Acad. Sci. U.S.A.
2005, 102, 13556−13561.
(26) Cui, Z.; Qiu, F. Synthetic double-stranded RNA poly(I:C) as a
potent peptide vaccine adjuvant: therapeutic activity against human
cervical cancer in a rodent model. Cancer Immunol. Immunother. 2006,
55, 1267−1279.
(27) Ichinohe, T.; Kawaguchi, A.; Tamura, S.; Takahashi, H.; Sawa,
H.; Ninomiya, A.; Imai, M.; Itamura, S.; Odagiri, T.; Tashiro, M.;
Chiba, J.; Sata, T.; Kurata, T.; Hasegawa, H. Intranasal immunization
with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor
agonist, protects mice against homologous and heterologous virus
challenge. Microbes Infect. 2007, 9, 1333−1340.
(9) Shukla, N. M.; Lewis, T. C.; Day, T. P.; Mutz, C. A.; Ukani, R.;
Hamilton, C. D.; Balakrishna, R.; David, S. A. Toward self-adjuvanting
subunit vaccines: model peptide and protein antigens incorporating
covalently bound toll-like receptor-7 agonistic imidazoquinolines.
Bioorg. Med. Chem. Lett. 2011, 21, 3232−3236.
(10) Shukla, N. M.; Malladi, S. S.; Day, V.; David, S. A. Preliminary
evaluation of a 3H imidazoquinoline library as dual TLR7/TLR8
antagonists. Bioorg. Med. Chem. 2011, 19, 3801−3811.
(11) Shukla, N. M.; Kimbrell, M. R.; Malladi, S. S.; David, S. A.
Regioisomerism-dependent TLR7 agonism and antagonism in an
imidazoquinoline. Bioorg. Med. Chem. Lett. 2009, 19, 2211−2214.
(12) Sabado, R. L.; O’Brien, M.; Subedi, A.; Qin, L.; Hu, N.; Taylor,
E.; Dibben, O.; Stacey, A.; Fellay, J.; Shianna, K. V.; Siegal, F.; Shodell,
M.; Shah, K.; Larsson, M.; Lifson, J.; Nadas, A.; Marmor, M.; Hutt, R.;
Margolis, D.; Garmon, D.; Markowitz, M.; Valentine, F.; Borrow, P.;
Bhardwaj, N. Evidence of dysregulation of dendritic cells in primary
HIV infection. Blood 2010, 116, 3839−3852.
(28) Houston, W. E.; Crabbs, C. L.; Stephen, E. L.; Levy, H. B.
Modified polyriboinosinic-polyribocytidylic acid, an immunological
adjuvant. Infect. Immun. 1976, 14, 318−319.
(29) Matsumoto, M.; Seya, T. TLR3: interferon induction by double-
stranded RNA including poly(I:C). Adv. Drug Delivery Rev. 2008, 60,
805−812.
(13) Fraietta, J. A.; Mueller, Y. M.; Do, D. H.; Holmes, V. M.;
Howett, M. K.; Lewis, M. G.; Boesteanu, A. C.; Alkan, S. S.; Katsikis,
P. D. Phosphorothioate 2′ deoxyribose oligomers as microbicides that
inhibit human immunodeficiency virus type 1 (HIV-1) infection and
block Toll-like receptor 7 (TLR7) and TLR9 triggering by HIV-1.
Antimicrob. Agents Chemother. 2010, 54, 4064−4073.
(14) Mandl, J. N.; Barry, A. P.; Vanderford, T. H.; Kozyr, N.; Chavan,
R.; Klucking, S.; Barrat, F. J.; Coffman, R. L.; Staprans, S. I.; Feinberg,
M. B. Divergent TLR7 and TLR9 signaling and type I interferon
production distinguish pathogenic and nonpathogenic AIDS virus
infections. Nature Med. 2008, 14, 1077−1087.
(15) Botos, I.; Segal, D. M.; Davies, D. R. The structural biology of
Toll-like receptors. Structure 2011, 19, 447−459.
(16) Jin, M. S.; Kim, S. E.; Heo, J. Y.; Lee, M. E.; Kim, H. M.; Paik, S.
G.; Lee, H.; Lee, J. O. Crystal structure of the TLR1−TLR2
heterodimer induced by binding of a tri-acylated lipopeptide. Cell
2007, 130, 1071−1082.
(17) Jin, M. S.; Lee, J. O. Structures of TLR−ligand complexes. Curr.
Opin. Immunol. 2008, 20, 414−419.
(18) Liu, L.; Botos, I.; Wang, Y.; Leonard, J. N.; Shiloach, J.; Segal, D.
M.; Davies, D. R. Structural basis of toll-like receptor 3 signaling with
double-stranded RNA. Science 2008, 320, 379−381.
(30) Cheng, K.; Wang, X.; Yin, H. Small-molecule inhibitors of the
TLR3/dsRNA complex. J. Am. Chem. Soc. 2011, 133, 3764−3767.
(31) Matsumoto, M.; Funami, K.; Oshiumi, H.; Seya, T. Toll-like
receptor 3: a link between toll-like receptor, interferon and viruses.
Microbiol. Immunol. 2004, 48, 147−154.
(32) Hoebe, K.; Beutler, B. LPS, dsRNA and the interferon bridge to
adaptive immune responses: Trif, Tram, and other TIR adaptor
proteins. J. Endotoxin Res. 2004, 10, 130−136.
(33) Sen, G. C.; Sarkar, S. N. Transcriptional signaling by double-
stranded RNA: role of TLR3. Cytokine Growth Factor Rev. 2005, 16,
1−14.
(34) Sioud, M. Innate sensing of self and non-self RNAs by Toll-like
receptors. Trends Mol. Med. 2006, 12, 167−176.
(35) Kawai, T.; Akira, S. Antiviral signaling through pattern
recognition receptors. J. Biochem. 2007, 141, 137−145.
(36) Uematsu, S.; Akira, S. Toll-like receptors and type I interferons.
J. Biol. Chem. 2007, 282, 15319−15323.
(19) Hemmi, H.; Kaisho, T.; Takeuchi, O.; Sato, S.; Sanjo, H.;
Hoshino, K.; Horiuchi, T.; Tomizawa, H.; Takeda, K.; Akira, S. Small
anti-viral compounds activate immune cells via the TLR7MyD88-
dependent signaling pathway. Nature Immunol. 2002, 3, 196−200.
(20) Gerster, J. F.; Lindstrom, K. J.; Miller, R. L.; Tomai, M. A.;
Birmachu, W.; Bomersine, S. N.; Gibson, S. J.; Imbertson, L. M.;
Jacobson, J. R.; Knafla, R. T.; Maye, P. V.; Nikolaides, N.; Oneyemi, F.
Y.; Parkhurst, G. J.; Pecore, S. E.; Reiter, M. J.; Scribner, L. S.;
Testerman, T. L.; Thompson, N. J.; Wagner, T. L.; Weeks, C. E.;
Andre, J. D.; Lagain, D.; Bastard, Y.; Lupu, M. Synthesis and
structure−activity relationships of 1H-imidazo[4,5-c]quinolines that
induce interferon production. J. Med. Chem. 2005, 48, 3481−3491.
(21) Weterings, J. J.; Khan, S.; van der Heden van Noort, G. J.;
Melief, C. J.; Overkleeft, H. S.; van der Burg, S. H.; Ossendorp, F.; Van
der Marel, G. A.; Filippov, D. V. 2-Azidoalkoxy-7-hydro-8-oxoadenine
derivatives as TLR7 agonists inducing dendritic cell maturation. Bioorg.
Med. Chem. Lett. 2009, 19, 2249−2251.
(22) Kurimoto, A.; Hashimoto, K.; Nakamura, T.; Norimura, K.;
Ogita, H.; Takaku, H.; Bonnert, R.; McInally, T.; Wada, H.; Isobe, Y.
Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-
like receptor 7 agonists introducing the antedrug concept. J. Med.
Chem. 2010, 53, 2964−2972.
(23) Adams, M.; Navabi, H.; Jasani, B.; Man, S.; Fiander, A.; Evans,
A. S.; Donninger, C.; Mason, M. Dendritic cell (DC) based therapy for
cervical cancer: use of DC pulsed with tumour lysate and matured with
a novel synthetic clinically non-toxic double-stranded RNA analogue
poly [I]:poly [C(12)U] (Ampligen R). Vaccine 2003, 21, 787−790.
(37) Kuznik, A.; Bencina, M.; Svajger, U.; Jeras, M.; Rozman, B.;
Jerala, R. Mechanism of endosomal TLR inhibition by antimalarial
drugs and imidazoquinolines. J. Immunol. 2011, 186, 4794−4804.
(38) Lee, J.; Chuang, T. H.; Redecke, V.; She, L.; Pitha, P. M.;
Carson, D. A.; Raz, E.; Cottam, H. B. Molecular basis for the
immunostimulatory activity of guanine nucleoside analogs: activation
of Toll-like receptor 7. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 6646−
6651.
(39) Gorden, K. B.; Gorski, K. S.; Gibson, S. J.; Kedl, R. M.; Kieper,
W. C.; Qiu, X.; Tomai, M. A.; Alkan, S. S.; Vasilakos, J. P. Synthetic
TLR agonists reveal functional differences between human TLR7 and
TLR8. J. Immunol. 2005, 174, 1259−1268.
(40) Gorski, K. S.; Waller, E. L.; Bjornton-Severson, J.; Hanten, J. A.;
Riter, C. L.; Kieper, W. C.; Gorden, K. B.; Miller, J. S.; Vasilakos, J. P.;
Tomai, M. A.; Alkan, S. S. Distinct indirect pathways govern human
NK-cell activation by TLR-7 and TLR-8 agonists. Int. Immunol. 2006,
18, 1115−1126.
(41) Kimbrell, M. R.; Warshakoon, H.; Cromer, J. R.; Malladi, S.;
Hood, J. D.; Balakrishna, R.; Scholdberg, T. A.; David, S. A.
Comparison of the immunostimulatory and proinflammatory activities
of candidate Gram-positive endotoxins, lipoteichoic acid, peptidogly-
can, and lipopeptides, in murine and human cells. Immunol. Lett. 2008,
118, 132−141.
1116
dx.doi.org/10.1021/jm2010207 | J. Med. Chem. 2012, 55, 1106−1116